DataMeds AI, Inc. (MEDS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 357.08%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 357.08% | Share-based compensation / revenue. Period ending 2026-06-30. $28.65M ÷ $8.02M × 100 ≈ 357.08% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 8.02M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 28.65M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -70.26M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $8.02M | $28.65M | $-70.26M | (m) | (m) | 357.08% | (m) | (m) |
| 2026-03-31 | (m) | $14.03M | $28.38M | $-68.42M | (m) | (m) | 202.22% | (m) | (m) |
| 2025-12-31 | (m) | $23.34M | $54.79M | $-93.75M | (m) | (m) | 234.79% | (m) | (m) |
| 2025-09-30 | (m) | $34.08M | (m) | $-72.14M | (m) | (m) | (m) | (m) | (m) |
| 2025-08-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $36.74M | (m) | $-42.34M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | $-37.41M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $18.13M | $1.08M | $-6.15M | (m) | (m) | 5.96% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $-2.88M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HWH International Inc. (HWH) | United States | $0.021B | -4.08 |
| Cosmos Health Inc. (COSM) | Greece | $0.038B | -0.60 |
| NU SKIN ENTERPRISES, INC. (NUS) | United States | $0.225B | -1.18 |
| HERBALIFE LTD. (HLF) | $1.281B | 8.39 | |
| CARDINAL HEALTH INC (CAH) | United States | $51.753B | 29.38 |
| Cencora, Inc. (COR) | United States | $59.130B | 20.57 |
| MCKESSON CORP (MCK) | United States | $101.317B | 19.78 |